×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
PR Newswire
PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on...
6 days ago
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
PR Newswire
Share this article ... LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ... (Nasdaq: INVA) (collectively, "Innoviva"),...
2 months ago
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
PR Newswire
(NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for...
5 months ago
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
PR Newswire
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva. Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata...
1 month ago
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
PR Newswire
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva. Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata...
2 months ago
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage ...
PR Newswire
Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of...
10 months ago
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)
Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report)'s stock had its “buy” rating reaffirmed by equities research analysts at HC...
3 days ago
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North ...
PR Newswire
Share this article ... LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ... The conference is being held November 2-4, 2023,...
6 months ago
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of ...
PR Newswire
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with...
7 months ago
Armata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic Advances
GuruFocus
Revenue: Reported grant revenue of $1.0 million for Q1 2024, which is below the estimated revenue of $1.10 million.
6 days ago